hepatitis c viral evolution in genotype 1 treatment-na？ve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials丙型肝炎病毒基因型1中进化treatment-na ve和接受telaprevir-based treatment-experienced患者治疗的临床试验.pdfVIP

下载本文档

2
0
约9.03万字
约 12页
2017-09-01 发布于上海
举报
版权申诉

hepatitis c viral evolution in genotype 1 treatment-na？ve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials丙型肝炎病毒基因型1中进化treatment-na ve和接受telaprevir-based treatment-experienced患者治疗的临床试验.pdf

1、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

hepatitis c viral evolution in genotype 1 treatment-na？ve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials丙型肝炎病毒基因型1中进化treatment-na ve和接受telaprevir-based treatment-experienced患者治疗的临床试验

Hepatitis C Viral Evolution in Genotype 1 Treatment- ¨ Naıve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials 1 2 1 1 1 1 Tara L. Kieffer *, Sandra De Meyer , Doug J. Bartels , James C. Sullivan , Eileen Z. Zhang , Ann Tigges , 2 1 1 1 1 2 Inge Dierynck , Joan Spanks , Jennifer Dorrian , Min Jiang , Bambang Adiwijaya , Anne Ghys , 2 1 1 3 4 Maria Beumont , Robert S. Kauffman , Nathalie Adda , Ira M. Jacobson , Kenneth E. Sherman , 5 1 6 Stefan Zeuzem , Ann D. Kwong , Gaston Picchio 1Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts, United States of America, 2 Janssen Infectious Diseases BVBA, Beerse, Belgium, 3 Weill Cornell Medical College, New York, New York, United States of America, 4 University of Cincinnati College of Medicine, Cincinnati, Ohio, United States of America, 5 Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany, 6 Janssen Research and Development, Titusville, New Jersey, United States of America Abstract Background: In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic changes could be observed in TVR-treated patients who did not achieve an SVR. Methods: Population sequence